肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2014年
5期
328-331
,共4页
靳美英%付小霞%田丽华%王素莲
靳美英%付小霞%田麗華%王素蓮
근미영%부소하%전려화%왕소련
乳腺肿瘤%蛋白,Periostin%血管内皮生长因子%基质金属蛋白酶9%免疫组织化学
乳腺腫瘤%蛋白,Periostin%血管內皮生長因子%基質金屬蛋白酶9%免疫組織化學
유선종류%단백,Periostin%혈관내피생장인자%기질금속단백매9%면역조직화학
Breast neoplasms%Protein,Periostin%Vascular endothelial growth factors%Matrix metalloproteinase 9%Immunohistochemistry
目的 探讨细胞外基质蛋白Periostin、血管内皮生长因子(VEGF)和基质金属蛋白酶-9(MMP-9)在乳腺浸润性导管癌中的表达差异及其与临床病理特征的关系.方法 应用免疫组织化学法检测58例乳腺浸润性导管癌组织和25例癌旁正常乳腺组织中Periostin、VEGF和MMP-9的表达水平.结果 在乳腺浸润性导管癌和正常乳腺组织中,Periostin的阳性率分别为63.8％(37/58)和0,VEGF的阳性率分别为69.0％(40/58)和8.0％(2/25),MMP-9的阳性率分别为70.7％(41/58)和16.0％(4/25),三者在两组间阳性率差异均有统计学意义(均P＜0.001).Periostin阳性率与TNM分期有关(x 2=4.835,P=0.028),与患者年龄、组织学分级、淋巴结转移均无关;VEGF阳性率与TNM分期、淋巴结转移有关(x2=4.230,P=0.040;x 2=9.667,P=0.002),与患者年龄、组织学分级无关(均P＞0.05);MMP-9阳性率与TNM分期、淋巴结转移有关(x2=8.456,P=0.004; x2=5.494,P=0.019),与患者年龄、组织学分级无关(均P＞ 0.05).Periostin、VEGF和MMP-9在乳腺浸润性导管癌组织中呈两两正相关(r分别为0.348、0.303、0.469,均P＜ 0.05).结论 Periostin、VEGF和MMP-9在乳腺浸润性导管癌的发生、发展及侵袭转移中起重要作用,它们在乳腺浸润性导管癌的表达两两相关.
目的 探討細胞外基質蛋白Periostin、血管內皮生長因子(VEGF)和基質金屬蛋白酶-9(MMP-9)在乳腺浸潤性導管癌中的錶達差異及其與臨床病理特徵的關繫.方法 應用免疫組織化學法檢測58例乳腺浸潤性導管癌組織和25例癌徬正常乳腺組織中Periostin、VEGF和MMP-9的錶達水平.結果 在乳腺浸潤性導管癌和正常乳腺組織中,Periostin的暘性率分彆為63.8％(37/58)和0,VEGF的暘性率分彆為69.0％(40/58)和8.0％(2/25),MMP-9的暘性率分彆為70.7％(41/58)和16.0％(4/25),三者在兩組間暘性率差異均有統計學意義(均P＜0.001).Periostin暘性率與TNM分期有關(x 2=4.835,P=0.028),與患者年齡、組織學分級、淋巴結轉移均無關;VEGF暘性率與TNM分期、淋巴結轉移有關(x2=4.230,P=0.040;x 2=9.667,P=0.002),與患者年齡、組織學分級無關(均P＞0.05);MMP-9暘性率與TNM分期、淋巴結轉移有關(x2=8.456,P=0.004; x2=5.494,P=0.019),與患者年齡、組織學分級無關(均P＞ 0.05).Periostin、VEGF和MMP-9在乳腺浸潤性導管癌組織中呈兩兩正相關(r分彆為0.348、0.303、0.469,均P＜ 0.05).結論 Periostin、VEGF和MMP-9在乳腺浸潤性導管癌的髮生、髮展及侵襲轉移中起重要作用,它們在乳腺浸潤性導管癌的錶達兩兩相關.
목적 탐토세포외기질단백Periostin、혈관내피생장인자(VEGF)화기질금속단백매-9(MMP-9)재유선침윤성도관암중적표체차이급기여림상병리특정적관계.방법 응용면역조직화학법검측58례유선침윤성도관암조직화25례암방정상유선조직중Periostin、VEGF화MMP-9적표체수평.결과 재유선침윤성도관암화정상유선조직중,Periostin적양성솔분별위63.8％(37/58)화0,VEGF적양성솔분별위69.0％(40/58)화8.0％(2/25),MMP-9적양성솔분별위70.7％(41/58)화16.0％(4/25),삼자재량조간양성솔차이균유통계학의의(균P＜0.001).Periostin양성솔여TNM분기유관(x 2=4.835,P=0.028),여환자년령、조직학분급、림파결전이균무관;VEGF양성솔여TNM분기、림파결전이유관(x2=4.230,P=0.040;x 2=9.667,P=0.002),여환자년령、조직학분급무관(균P＞0.05);MMP-9양성솔여TNM분기、림파결전이유관(x2=8.456,P=0.004; x2=5.494,P=0.019),여환자년령、조직학분급무관(균P＞ 0.05).Periostin、VEGF화MMP-9재유선침윤성도관암조직중정량량정상관(r분별위0.348、0.303、0.469,균P＜ 0.05).결론 Periostin、VEGF화MMP-9재유선침윤성도관암적발생、발전급침습전이중기중요작용,타문재유선침윤성도관암적표체량량상관.
Objective To investigate the expression and significance of Periostin,VEGF and MMP-9 in breast invasive ductal carcinoma.Methods Immunohistochemistry was employed to detect the expression of Periostin,VEGF and MMP-9 in breast invasive ductal carcinoma and normal breast tissue.Results In breast invasive ductal carcinoma and normal breast tissue,the positive rates of Periostin were 63.8 ％ (37/58) and 0 (x2 =24.272,P =0.000).The figures were 69 ％ (40/58) and 8 ％ (2/25) for the positive rates of VEGF (x2 =25.977,P =0.000),respectively,as well as 70.69 ％ (41/58) and 16.0 ％ (4/25) for the positive rates of MMP-9 (x2 =21.050,P =0.000),respectively.There were significant differences among the groups (P ＜ 0.05).In breast invasive ductal carcinoma,the expression of Periostin was correlated with clinical stage (x2 =4.835,P =0.028),whereas not correlated with age (x2 =1.155,P=0.282),histological grade (x2 =0.05,P =0.972),lymphatic metastasis (x2 =1.660,P =0.198).The expression of VEGF was correlated with clinical stage (x2 =4.230,P =0.040),lymphatic metastasis (x2 =9.667,P =0.002),whereas not correlated with age (x2 =0.506,P =0.477),histological grade (x2 =0.532,P =0.767).The expression of MMP-9 was correlated with clinical stage (x2 =8.456,P =0.004),lymphatic metastasis (x2 =5.494,P =0.019),whereas not correlated with age (x2 =0.153,P =0.695),histological grade (x2 =0.224,P =0.894).The expression of Periostin,VEGF and MMP-9 were positively correlated with each other in breast invasive ductal carcinoma (r =0.348,P =0.001; r =0.303,P =0.021; r =0.469,P =0.000).Conclusion Periostin,VEGF and MMP-9 are correlated closely with the occurrence and development of breast invasive ductal carcinoma,which might be valuable in evaluating the invasiveness,metastasis and prognosis.
